Zynex (ZYXIQ) promised record revenue, explosive order growth, and compliance-focused messaging. Prosecutors say the growth came from shipping piles of supplies patients never needed. Why does it matter? Insurers pushed back, the payments froze, and the stock collapsed 51% in one day.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zynex is facing a federal securities lawsuit that says the company’s reported growth and compliance disclosures masked a long-running billing scheme and other problems that later surfaced in financial results, internal changes, a bankruptcy filing, and a federal indictment. The complaint says investors were hit by stock drops after corrective disclosures tied to Tricare payment suspensions, compliance admissions, and bankruptcy news, and it puts the class period at February 25, 2021, through December 15, 2025.
Investors who traded Zynex during the class period may want to review the allegations closely and check whether they could be affected.
Company Background
The complaint says Zynex is a medical device manufacturer founded by Thomas Sandgaard in 1996 and based in Englewood, Colorado. It says the company manufactures and markets electrotherapy devices for pain management and physical rehabilitation, and that it operates through Zynex Medical, Zynex Monitoring Solutions, and Zynex NeuroDiagnostics. The complaint also says Zynex generated substantially all of its revenue from these electrotherapy products, with recurring revenue tied in large part to surface electrodes and batteries sent to existing patients.
Core Allegations
The lawsuit centers on the complaint’s claim that Zynex’s reported growth was not driven by product demand alone, but by excessive and unnecessary shipments and improper billing to payors. It alleges that management prioritized aggressive sales activity over compliance, while failing to disclose that the company’s billing practices were drawing scrutiny from insurers and regulators. The complaint says those alleged omissions and misstatements made Zynex’s public statements about growth, operations, and prospects materially misleading.
Readers following the case may want to watch how the complaint frames the company’s disclosures versus the later revelations.
Management Statements
According to the complaint, Sandgaard said on a February 25, 2021, conference call that increased revenues were tied to “good order flow” and strong relationships with prescribers. The complaint says Lucsok later stated on July 28, 2022, that the company had seen a “consistent increase in order growth and revenue” due in large part to sales force productivity. According to the complaint, Sandgaard stated on March 13, 2023, that Zynex was seeing increased sales rep productivity and had received the highest number of prescriptions in the company’s history in the fourth quarter.
The complaint further quotes Lucsok, on April 30, 2024, as attributing success to sales reps meeting targets and to a strong pipeline with prescribers. It says Sandgaard later told investors on October 24, 2024, that Zynex’s success was due to better pain management and monitoring solutions for patients, doctors, and hospitals. The complaint alleges these and similar statements were misleading because they omitted the alleged overbilling and over-shipping scheme.
Corrective Disclosures
On March 11, 2025, Zynex reported fourth-quarter and full-year 2024 results and disclosed a significant revenue shortfall in the quarter due to slower-than-normal payments from certain payors. The company also said Tricare had temporarily suspended payments while reviewing prior claims, and the complaint says Tricare represented about 20% to 25% of annual revenue. The complaint says Zynex’s stock fell 51.3% to close at $3.41 on March 12, 2025, after that disclosure.
On July 31, 2025, the company said it was refocusing its business strategy, and Lucsok stated that Zynex had revamped its sales compensation model to support regulatory compliance. The complaint says the company also disclosed leadership changes, including the appointment of a new CEO and the announced departure of its CFO. It says the stock fell 45% on August 1, 2025, from $2.23 to $1.26, after those admissions.
The complaint also says Zynex filed for Chapter 11 bankruptcy on December 15, 2025. It alleges the stock fell about 50% and closed at 34 cents on December 16, 2025. Finally, the complaint says a federal indictment was unsealed on January 21, 2026, charging Sandgaard and Lucsok with, among other counts, conspiracy to commit health care fraud, mail fraud, and securities fraud.
Why This Matters to Investors
The complaint argues that investors bought Zynex shares unaware that the company’s reported growth and revenue trends were allegedly inflated by improper billing and excessive shipments. It says the later disclosures about Tricare payment suspensions, compliance problems, leadership changes, bankruptcy, and the indictment helped reveal the alleged truth behind the company’s financial results. For shareholders who bought during the class period, the complaint claims those disclosures were tied to major share-price declines and therefore to investor losses.
Legal Claims
The complaint says the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5, and asserts claims under Section 20(a) for controlling-person liability. It says the allegedly false or misleading statements concerned Zynex’s business, revenue growth, compliance with payor rules, internal controls, and the nature of its order growth. The complaint also alleges deceptive conduct by certain audit committee members under Rule 10b-5 subsections (a) and (c).
Investors who want to understand their rights may want to review the case allegations in full.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.